|Bid||409.36 x 800|
|Ask||411.94 x 800|
|Day's range||406.99 - 412.48|
|52-week range||317.06 - 664.70|
|Beta (5Y monthly)||1.14|
|PE ratio (TTM)||53.54|
|Earnings date||31 Jan 2023 - 06 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||480.63|
IDEXX's (IDXX) Q3 top-line performance rides on strong CAG Diagnostics recurring revenue growth.
Shares of IDEXX Laboratories (NASDAQ: IDXX) were moving higher today after the veterinary healthcare company posted better-than-expected results in its third-quarter earnings but slashed its full-year earnings guidance due to the stronger dollar and higher interest rates. The company said overall revenue was up 4% in the quarter to $841.7 million, but organic sales, which adjust for currency headwinds, increased 8%. Organic revenue in U.S. pet diagnostics, its biggest business segment, was up 10%, and the company saw 14% growth in its global premium installed instrument base, which bodes well for future sales.
Idexx (IDXX) delivered earnings and revenue surprises of 5.39% and 1.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?